Resolve Therapeutics is pioneering safe, targeted therapies for underserved patients with autoimmune diseases. Our lead program, RSLV-132, is designed to prevent chronic, systemic inflammation that may cause organ damage and the symptoms associated with autoimmune diseases. RSLV-132 is a first-in-class RNase-Fc fusion protein being developed to treat patients with lupus and Sjögren’s syndrome. We have successfully completed a Phase 2a study in SLE (insert link to Dec 8, 2020 press release) and will be initiating a Phase 3 study in Sjögren’s syndrome in 2022.
OUR COMPANY
Management Team
Founder,
Chief Executive Officer Member,
Board of Managers
James Posada, Ph.D., MBA, is founder and Chief Executive Officer…
read more
James Posada, PH.D., MBA
Founder and Chief Executive Officer
James Posada, Ph.D., MBA, is founder and Chief Executive Officer of Resolve Therapeutics. Previously, James was Chief Business Officer of GlycoFi, where he designed the business strategy and executed partnerships, including the 2006 sale of the company to Merck. James is a scientist who has made important contributions to the field of signal transduction, including the identification and cloning of the first full length MAP kinase ERK2, and identifying the upstream activating kinase MEK. Following his postdoctoral training with Jonathan Cooper, he was a faculty member at the University of Vermont School of Medicine where he built an NIH-funded basic research group. From academics, James pivoted into drug discovery, joining Eli Lilly where he led multiple research groups as a member of the biotherapeutics management team.
Close
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical…
read more
Peter Kiener, PH.D.
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical development. He previously served as Chief Scientific Officer of Ambrx Inc., a clinical stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior, he was President and co-founder of Zyngenia Inc., an early stage biopharmaceutical company. He held leadership roles at MedImmune, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor, and the University of Massachusetts at Amherst, where he was a Research Associate. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. He has published more than 120 papers in peer-reviewed journals, and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a Bachelor’s degree in chemistry from the University of Lancaster and a Doctorate of Philosophy in biochemistry from the University of Oxford.
Close
Member, Board of Managers
Somu Subramaniam, Member, Board of Managers
read more
Somu Subramaniam
Member, Board of Managers
Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
Close